Tim Walsteijn

1PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|May 17, 2025
A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands.

David Smalbrugge, Tim Walsteijn, Jeantine de Feijter

Pageof 1

Frequent Collaborators